Two Sigma Investments, LP Relmada Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

$41.6 Billion
Q4 2024

A detailed history of Two Sigma Investments, LP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 127,579 shares of RLMD stock, worth $42,101. This represents 0.0% of its overall portfolio holdings.

Number of Shares

127,579

Previous 191,315 33.31%

Holding current value

$42,101

Previous $619,000 89.34%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.35 - $3.65 $22,307 - $232,636	-63,736 Reduced 33.31%	127,579 $66,000
Q3 2024 Nov 14, 2024	SELL	$2.3 - $4.36 $27,475 - $52,084	-11,946 Reduced 5.88%	191,315 $619,000
Q2 2024 Aug 14, 2024	SELL	$2.93 - $4.94 $69,669 - $117,463	-23,778 Reduced 10.47%	203,261 $609,000
Q1 2024 May 15, 2024	SELL	$3.1 - $6.8 $234,685 - $514,794	-75,705 Reduced 25.01%	227,039 $1.06 Million
Q4 2023 Feb 14, 2024	BUY	$2.45 - $4.22 $258,590 - $445,408	105,547 Added 53.52%	302,744 $1.25 Million
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $267,068 - $408,141	-107,689 Reduced 35.32%	197,197 $591,000
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $220,643 - $351,837	-99,389 Reduced 24.58%	304,886 $750,000
Q1 2023 May 15, 2023	SELL	$2.24 - $4.76 $275,266 - $584,942	-122,887 Reduced 23.31%	404,275 $913,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $35.84 $1.03 Million - $17 Million	475,274 Added 915.96%	527,162 $1.84 Million
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $741,827 - $1.5 Million	40,537 Added 357.12%	51,888 $1.92 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $14,041 - $25,819	851 Added 8.1%	11,351 $216,000
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $175,560 - $283,395	10,500 New	10,500 $283,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

8.29M

Call Options Held

364K

Put Options Held

46.5K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $9.44M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account

Two Sigma Investments, LP Relmada Therapeutics, Inc. Transaction History